Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
3(50.0%)
Phase 4
1(16.7%)
Phase 2
1(16.7%)
Early Phase 1
1(16.7%)
6Total
Phase 1(3)
Phase 4(1)
Phase 2(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT04480645Early Phase 1Completed

CivaDerm(TM) Surface Therapy Pilot Study

Role: lead

NCT04033081Phase 4Active Not Recruiting

Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®

Role: lead

NCT02843945Phase 1Recruiting

Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

Role: lead

NCT03290534Phase 2Recruiting

Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

Role: lead

NCT02902107Phase 1Completed

Intraoperative Radiation Therapy for Locally Advanced or Recurrent Abdomino-pelvic Solid Tumors With the CivaSheet

Role: collaborator

NCT03109041Phase 1Completed

Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source

Role: lead

NCT02516709Completed

Linear Source Registry for Prostate Cancer

Role: lead

All 7 trials loaded